TFEB Activating Small Molecules for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's lack effective methods to prevent the accumulation of toxic protein aggregates due to limitations in autophagy enhancement and lysosome biogenesis, particularly due to poor blood-brain barrier permeability and MTOR pathway inhibition complications.
Innovation Solution
Development of small lipid molecule mono-carbonyl analogs of curcumin, specifically compounds A2, B3, and C1, which activate TFEB without inhibiting the MTOR pathway, enhancing autophagy and lysosome biogenesis, and are capable of crossing the blood-brain barrier for neuronal and non-neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MTOR inhibitors (rapamycin, torin1) are used to activate TFEB, then autophagy enhancement is achieved, but pharmacokinetic profile and side effects worsen making them unsuitable for long-term use
Solution Approach 1:
The patent introduces disaccharides (trehalose, sucrose) as intermediary compounds that activate TFEB through an MTOR-independent pathway. These disaccharides serve as mediators between the therapeutic goal (TFEB activation) and the constraint (avoiding MTOR inhibitor side effects), providing a safer alternative for long-term treatment of neurodegenerative diseases.
Solution Approach 2:
The invention changes the activation mechanism parameter from MTOR-dependent (rapamycin/torin1 pathway) to MTOR-independent (disaccharide pathway). This parameter change allows TFEB activation to occur without engaging the problematic MTOR inhibition pathway, thereby eliminating the associated side effects while maintaining therapeutic efficacy.
2Object-affected harmful factors
If disaccharides (trehalose, sucrose) are used to activate TFEB in an MTOR-independent manner, then side effects are reduced, but blood-brain barrier permeability worsens
Solution Approach 1:
The patent modifies the chemical structure of disaccharides by adding specific functional groups or molecular modifications that enhance their ability to cross the blood-brain barrier while maintaining their MTOR-independent TFEB activation capability. This local structural modification improves the delivery efficiency to the brain without compromising the beneficial side effect profile.
3Ease of operation
If current treatments are used for neurodegenerative diseases, then some symptomatic relief may be achieved, but prevention of toxic protein aggregate accumulation worsens due to poor autophagy enhancement
Solution Approach 1:
The patent enables continuous long-term administration of disaccharide-based compounds to maintain sustained TFEB activation and autophagy enhancement. Unlike MTOR inhibitors that require intermittent dosing due to side effects, the disaccharide compounds can be administered continuously over extended periods, providing ongoing prevention of toxic protein aggregate accumulation in neurodegenerative diseases.
Data Source
AI summary
The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.